To the full analysis
Eli Lilly stock: growth
LLYEli Lilly reported $65.18B in revenue for fiscal 2025, up 44.7% on the prior year, up 21.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7.8%
per year from 2006 to 2025, per share 8.9%
Earnings (Annual rate)
11.4%
per year from 2006 to 2025, per share 12.5%
Free cash flow (Annual rate)
6.1%
per year from 2006 to 2025, per share 7.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 21.6% | 12.6% | 7.8% |
| Revenue per share | 23.1% | 14.9% | 8.9% |
| Earnings | 27.2% | 24.0% | 11.4% |
| Earnings per share | 29.0% | 26.6% | 12.5% |
| Free cash flow | 14.9% | 21.0% | 6.1% |
| Free cash flow per share | 16.4% | 23.5% | 7.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $15.69B | $2.66B | $2.9B |
| 2007 | $18.63B | $2.95B | $4.07B |
| 2008 | $20.37B | −$2.07B | $6.35B |
| 2009 | $21.84B | $4.33B | $3.48B |
| 2010 | $23.08B | $5.07B | $5.67B |
| 2011 | $24.29B | $4.35B | $5.54B |
| 2012 | $22.6B | $4.09B | $4.26B |
| 2013 | $23.11B | $4.68B | $4.64B |
| 2014 | $19.62B | $2.39B | $2.89B |
| 2015 | $19.96B | $2.41B | $1.34B |
| 2016 | $21.22B | $2.74B | $3.76B |
| 2017 | $19.97B | −$204.1M | $3.45B |
| 2018 | $21.49B | $3.23B | $2.51B |
| 2019 | $22.32B | $8.32B | $3.48B |
| 2020 | $24.54B | $6.19B | $4.47B |
| 2021 | $28.32B | $5.58B | $5.39B |
| 2022 | $28.54B | $6.24B | $4.6B |
| 2023 | $34.12B | $5.24B | −$3.15B |
| 2024 | $45.04B | $10.59B | $3.76B |
| 2025 | $65.18B | $20.64B | $8.97B |
Revenue by segment
How Eli Lilly and Company makes its money and how that has shifted. Names are as the company reports them.
- Product94%
- Collaboration and Other Revenue6%
Figures as a table
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|
| Product | $20.38B | $22.69B | $25.96B | $25.46B | $28.81B | $40.75B | $60.96B | 93.5% |
| Collaboration and Other Revenue | $1.94B | $1.85B | $2.36B | $3.08B | $5.31B | $4.29B | $4.22B | 6.5% |
| Total revenue | $22.32B | $24.54B | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B | 100% |
Revenue by region
Where Eli Lilly and Company generates its revenue.
- United States67%
- Europe18%
- Outside the US9%
- Japan3%
- China3%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| United States | $16.81B | $18.19B | $21.79B | $30.38B | $43.48B | 66.7% |
| Europe | $4.78B | $4.3B | $6.17B | $6.92B | $11.56B | 17.7% |
| Outside the US | $2.7B | $2.85B | $2.95B | $4.27B | $6.06B | 9.3% |
| Japan | $2.37B | $1.75B | $1.67B | $1.81B | $2.13B | 3.3% |
| China | $1.66B | $1.45B | $1.54B | $1.66B | $1.95B | 3% |
| Total revenue | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.